TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04205786

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: Vitamin B12, orally, 2500 mcg, daily, for 90 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood collection for laboratory testing will occur within 10 days of signing the consent form, on day 45 +/- 10 days, and on day 90 +/- 10 days. It will include:~1. Serum B12 levels~2. CRP~3. Homocysteine level~4. MMA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory - Short Form survey
Description: Brief Pain Inventory - Short Form survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory - Short Form survey
Description: Brief Pain Inventory - Short Form survey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACT-ES Trial Outcome Index (Version 4)
Description: FACT-ES Trial Outcome Index (Version 4)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-ES Trial Outcome Index (Version 4)
Description: FACT-ES Trial Outcome Index (Version 4)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire to Assess Adherence to Aromatase Inhibitors
Description: Questionnaire to Assess Adherence to Aromatase Inhibitors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire to Assess Adherence to Aromatase Inhibitors
Description: Questionnaire to Assess Adherence to Aromatase Inhibitors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demographics Questionnaire
Description: Demographics Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographics Questionnaire
Description: Demographics Questionnaire
Study: NCT05014919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT05885594

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]NOS
Description: \[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.

Intervention type: DRUG
Group type: OTHER
Intervention: [18F]NOS
Description: \[18F\]-6-(2-fluoro-propyl)-4-methylpyridin-2-amine, also known as \[18F\]NOS, is a positron emitting radiopharmaceutical that has been studied in animals and humans which permits the visualization and measurement by positron emission tomography (PET/CT) imaging of in vivo iNOS expression as a marker of inflammation.
Study: NCT05570162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes educational program
Description: 30-minute long diabetes educational program
Study: NCT06583655

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLND(clinical low risk)
Description: treated with whole breast irradiation(WBI)alone 50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx or no PMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLND(clinical high risk, genomic low risk)
Description: treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SLND alone ,clinical high risk and genomic high risk group
Description: treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node Irradiation+ axillary +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Dissection(SLND) + axillary lymph node dissection(ALND)
Description: treated with whole breast irradiation(WBI)/Post-Mastectomy Adjuvant Radiotherapy(PMRT) + regional node irradiation (Internal Mammary Node +supraclavicular radiotherapy),the radiation dose could be conventional radiation or hypo-fraction irradiation:50Gy/25Fx + 10Gy/5Fx or 40Gy/15Fx + 10Gy/4Fx
Study: NCT06583343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Botulinum toxin injections were administered in appropriate doses to the spastic muscles of children with cerebral palsy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional rehabilitation program; consisting of walking-balance exercises, range of motion exercises, stretching, and strengthening exercises, was provided for 1 hour, 5 days a week, totaling 30 sessions
Study: NCT04708847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GYM329
Description: GYM329 subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GYM329
Description: GYM329 subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05218109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS
Description: transcutaneous vagus nerve stimulation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: Brightmind mobile mindfulness application

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindfulness
Description: Brightmind mobile mindfulness application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Brightmind mobile mindfulness application

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tVNS
Description: sham transcutaneous vagus nerve stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Number Puzzle
Description: Control number puzzle task delivered via mobile device
Study: NCT04657991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study: NCT06460363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (TACS)
Description: Transcranial alternating sinusoidal current at frequency of 40 Hz applied for 60 min through a pair of saline-soaked surface sponge electrodes.
Study: NCT05781451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3361237
Description: All patients will receive LY3361237 450mg subcutaneously every 2 weeks for a total of 12 weeks.
Study: NCT06501976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: 2.6 mg/m2 , Given IV, every 21 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Thoracic radiotherapy
Study: NCT06460363

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TACS
Description: Sham treatment with few seconds of actual electrical current and same electrode configuration
Study: NCT04379830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very Low Energy Diet
Description: Optifast 900 is an FDA approved commercial nutritionally complete meal replacement product manufactured and marketed in the United States. Optifast 900 will be employed as part of the VLED in the present study in the following manner: Optifast 900 with a single piece of fruit for breakfast, Optifast 900 with one cup of vegetables for lunch, and Optifast 900 with one cup of vegetables for dinner. Patients will be provided written information on fruits and vegetables permitted for consumption with Optifast 900 to provide a total energy intake between 450 and 800 kilocalories (kcal) per day.
Study: NCT05006755

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: Mineral Trioxide Aggregate stimulates cementoblasts to produce matrix for cementum formation and is biocompatible with the periradicular tissues thus shows a superior sealing ability when used in perforation repair

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine has a good sealing ability, high compressive strengths, short setting time, biocompatibility, bioactivity and biomineralization properties that make it available to be used in endodontic repair procedures
Study: NCT06274177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-785-7
Description: Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment
Study: NCT05406713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg intravenously
Study: NCT05641116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: 24 face-to-face APA sessions at the sport and health center for 3 months at a rate of 2 sessions per week near his home and 9 therapeutic patient education workshops for 3 months at a rate of 3 workshops per month (telecare).

Intervention type: OTHER
Group type: OTHER
Intervention: Advice and recommendations of physical activity at home
Description: Advice and recommendations of physical activity at home (= current clinical practice in autonomy for 3 months).
Study: NCT04951193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy app
Description: Goal2QuitVaping focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual
Description: Participants will be provided educational material about quitting vaping nicotine with the suggestion to discuss questions with their PCP. Participants will be asked to complete questionnaire measures weekly for 4 weeks following study enrollment.
Study: NCT05995626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronidase
Description: hyaluronidase injection is used during fluid administration under the skin to help achieve hydration, to increase the dispersion and absorption of other injected drugs, or during some types of urography (imaging of the urinary tract) to help improve resorption of drugs used during the procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: co2 laser
Description: CO2 lasers use an aiming beam to see where the treatment beam will impact the focus tissue. The focus tissue will then be cleanly incised. They have greater precision for laser surgery and have more flexibility in tip sizes and protocols.
Study: NCT05712681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: T : JP-1366 20mg tablet after the meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: T : JP-1366 20mg tablet after the meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: R : JP-1366 20mg tablet under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JP-1366 20mg tablet
Description: R : JP-1366 20mg tablet under fasting condition
Study: NCT05479370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax Quadrivalent vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT05383482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Afuresertib 125 mg PO on days 1-5, 8-12, 15-19 or Afuresertib 125 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 80 mg/M2 IV D1,8, Q3W or 100 mg/M2 IV D1,8, Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50 mg/M2 IV D1 Q3W or Docetaxel 60 mg/M2 IV D1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200 mg Q3W
Study: NCT05164653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril Valsartan Sodium Hydrate
Description: Switch from the ACE inhibitor or ARB that was taken before the allocation, and start oral administration twice daily with a starting dose of 50 mg of sacubitril valsartan. The duration of administration of the ACE inhibitor or ARB before allocation does not matter, but when switching from the ACE inhibitor, administration of sacubitril valsartan should be started at least 36 hours after the final administration of the drug.~After the start of administration, the dose is gradually increased to 100 mg and 200 mg once at intervals of 2 to 4 weeks, referring to the latest package insert and safety and tolerability standards. At that time, if the doctor in charge determines that the dose is not tolerated after the dose is increased, the dose may be reduced to the previous dose or the drug may be suspended depending on the medical situation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment, other than Sacubitril Valsartan Sodium Hydrate, for HF
Study: NCT05789290

Intervention type: DEVICE
Intervention: Hilotherm cryocompression device
Description: An electronic device that is capable of circulating warm or cooled water at a user-selected temperature between 10-30℃. Water is circulated from a central unit, through a tube, to a cuff wrapped around the intended therapy area (the knee). A treatment lasts for 30-minutes, at which point the device is turned off and the cuff is removed from the limb of the user.
Study: NCT05422482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1123
Description: ICV-administered Hunterase, Idursulfase-ß
Study: NCT04983030

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.Mos4.HIV
Description: Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-HIV
Description: MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA-BN-HIV
Description: MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121
Description: PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGT121
Description: PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400
Description: PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGDM1400
Description: PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRC07-523LS
Description: VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Study: NCT06638905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Babor Ultimate ECM Repair Serum
Description: The BABOR® Ultimate ECM Repair Serum contains Biogen plant extract, cotton thistle flower, and wakame extract. Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Babor Cure Cream
Description: Babor products are encouraged to be used simultaneously mornings and/or evenings to reinforce the skin's protective barrier, promote vibrant skin, and restore skin elasticity and firmness.
Study: NCT06644443

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-GPRC5D CAR-T cells
Description: patient was subjected to 2-5×10\^6 BCMA-GPRC5D CAR-T cells/kg
Study: NCT06645171

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre drink
Description: One drink will be tested

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fibre drink
Description: One drink will be tested
Study: NCT06640478

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NUTRI-Beta Counseling
Description: Dietary Counseling focused on anti-inflammatory foods

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Standard dietary counseling
Description: Standard of Care therapy: Nutrition counseling per the ADA clinical guidelines and USDA MyPlate model

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Free weekly produce foods
Description: Free weekly produce
Study: NCT06161493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: A bromodomain extra-terminal inhibitor (BETi) that blocks a group of proteins called bromodomain and extra-terminal (BET), which may counteract the effect of NSD3 on tumor growth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: An anti-cancer medication (PARP inhibitor) used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer .
Study: NCT05946551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Cetirizine will be dispensed as a 10mg capsule with instructions for patients to take one capsule daily by mouth, preferably at bedtime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine will be dispensed in 20mg capsules with instructions for patients to take one capsule twice daily, as close to the same times every day as possible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine Placebo
Description: The cetirizine placebo will be designed as a capsule of an inert substance and will match the morphology of the cetirizine treatment capsule. Administration instructions to match that of cetirizine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Famotidine Placebo
Description: The famotidine placebo will be designed as a capsule of an inert substance and will match the morphology of the famotidine treatment capsule. Administration instructions to match that of famotidine.
Study: NCT06114368

Intervention type: PROCEDURE
Intervention: Surgery for the treatment of Acute Achilles tendon rupture
Description: Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared

Intervention type: PROCEDURE
Intervention: Surgery for the treatment of Acute Achilles tendon rupture
Description: Two different surgical techniques were applied in two different patient groups for the same disease. Their outcomes are evaluated and compared
Study: NCT05427929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NVR 4mm Edi catheter
Description: Receive NAVA ventilation using the newly designed NVR 4 mm Edi catheter
Study: NCT05116137

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit-based resistance exercise (CRT)
Description: CRT is a common training method used to foster aerobic fitness, muscular endurance and strength, as well as neuromuscular adaptations in one workout. CRT is comprised of several sets of different exercises with little rest in between each set.
Study: NCT05136495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeinated coffee - decaffeinated coffee
Description: Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeinated coffee - decaffeinated coffee
Description: Drink caffeinated coffee one morning and drink decaffeinated coffee the other morning
Study: NCT05995574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: avatar communication training
Description: Avatar simulates a mother and a daughter for the pediatrician to practice communication about contraception.
Study: NCT06111508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Description: A Continuous Glucose Monitoring (CGM)-based once weekly titration algorithm of basal insulin as implemented in DiAs Cloud platform
Study: NCT05165238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of four week coaching program on dietary habits
Description: A registered dietitian will provide dietary coaching via online groups to participants.